PPIO-006 Primary Tumor Resection for IVa NSCLC
- Conditions
- Non-small-cell Lung Cancer (NSCLC)
- Interventions
- Procedure: Primary tumor resection or not
- Registration Number
- NCT06232967
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Brief Summary
The goal of this mutli-center observational study is toinvestigate the impact of primary tumor resection (PTR) on the long-term survival of patients with non-small-cell lung cancer (NSCLC) and dry pleural dissemination (DPD). The main question it aims to answer is: whether primary tumor resection improve long-term survival of NSCLC patients with dry pleural dissemination.
- Detailed Description
Non-small-cell lung cancer (NSCLC) patients with dry pleural dissemination have poor survival rates and are generally contraindicated for surgery. Previous single-center retrospective studies have suggested that these patients may benefit from primary tumor resection (PTR). However, the evidence supporting PTR is still limited, especially in the era of targeted therapy. This study aimed to investigate the impact of PTR on the long-term survival of patients with NSCLC and DPD.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 223
(1) pathologically confirmed primary NSCLC with malignant pleural dissemination, (2) no preoperative treatment, (3) age 80 years or younger, (4) clinicopathologic data and follow-up results were complete.
(1) pleural effusion, contralateral lung metastasis or distant metastasis revealed preoperatively, and (2) with a history of other malignant disease.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Primary tumor resection (PTR group) Primary tumor resection or not includes wedge resection, segmentectomy, or lobectomy.
- Primary Outcome Measures
Name Time Method Disease-specific survival (DSS) Up to 8 years The duration from the day of surgery to the the last follow-up visit or to death specifically caused by NSCLC.
- Secondary Outcome Measures
Name Time Method Progression-free survival (PFS) Up to 8 years The duration of survival with no evidence of progression of the disease.
Trial Locations
- Locations (1)
Army Medical Center of the People's Liberation Army
🇨🇳Chongqing, Chongqing, China